ArticleNature biomedical engineering2020
Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs.
Article in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 73 citations in OpenAlex.
- Paracrine Factor Local Gradient-Generating System for Engineering Perfusable Vascularized Hepatocyte Tissues with Perfusion-Induced Proliferation.Advanced healthcare materials · 2026Article
- Microenvironmental determinants of endothelial cell heterogeneity.Nature reviews. Molecular cell biology · 2025Review
- Immune-privileged cord blood-derived endothelial colony-forming cells: advancing immunomodulation and vascular regeneration.Angiogenesis · 2025Review
- [Liver organoid technology and its related progress in liver disease research].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Isolation, characterization, and vascular potential of porcine cells in a three-dimensional decellularized liver matrix model.Frontiers in bioengineering and biotechnology · 2025Article
- Liver tissue engineering using decellularized scaffolds: Current progress, challenges, and opportunities.Bioactive materials · 2024Review
- Two Decades of Advances and Limitations in Organ Recellularization.Current issues in molecular biology · 2024Review
- The Prospect of Hepatic Decellularized Extracellular Matrix as a Bioink for Liver 3D Bioprinting.Biomolecules · 2024Review
- First Application of a Mixed Porcine-Human Repopulated Bioengineered Liver in a Preclinical Model of Post-Resection Liver Failure.Biomedicines · 2024Article
- Decellularized extracellular matrix biomaterials for regenerative therapies: Advances, challenges and clinical prospects.Bioactive materials · 2024Review
- Metallization of Targeted Protein Assemblies in Cell-Derived Extracellular Matrix by Antibody-Guided Biotemplating.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Manufacturing and Functional Characterization of Bioengineered Liver Grafts for Extracorporeal Liver Assistance in Acute Liver Failure.Bioengineering (Basel, Switzerland) · 2023Article
- Decellularization Techniques for Tissue Engineering: Towards Replicating Native Extracellular Matrix Architecture in Liver Regeneration.Journal of functional biomaterials · 2023Review
- Whole Liver Derived Acellular Extracellular Matrix for Bioengineering of Liver Constructs: An Updated Review.Bioengineering (Basel, Switzerland) · 2023Review
- 3D Printing of Microenvironment-Specific Bioinspired and Exosome-Reinforced Hydrogel Scaffolds for Efficient Cartilage and Subchondral Bone Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Cell transplantation-based regenerative medicine in liver diseases.Stem cell reports · 2023Review
- Bioengineering liver tissue by repopulation of decellularised scaffolds.World journal of hepatology · 2023Review
- Bioengineered liver crosslinked with nano-graphene oxide enables efficient liver regeneration via MMP suppression and immunomodulation.Nature communications · 2023Article
- Review
- Sustained in vivo perfusion of a re-endothelialized tissue engineered kidney graft in a human-scale animal model.Frontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 3 institutions in 2 countries.
Funding
Abstract
Implanted bioengineered livers have not exceeded three days of continuous perfusion. Here we show that decellularized whole porcine livers revascularized with human umbilical vein endothelial cells and implanted heterotopically into immunosuppressed pigs whose spleens had been removed can sustain perfusion for up to 15 days. We identified peak glucose consumption rate as a main predictor of the patency of the revascularized bioengineered livers (rBELs). Heterotopic implantation of rBELs into pigs in the absence of anticoagulation therapy led to sustained perfusion for three days, followed by a pronounced immune responses directed against the human endothelial cells. A 10 day steroid-based immunosuppression protocol and a splenectomy at the time of rBEL implantation reduced the immune responses and resulted in continuous perfusion of the rBELs for over two weeks. We also show that the human endothelial cells in the perfused rBELs colonize the liver sinusoids and express sinusoidal endothelial markers similar to those in normal liver tissue. Revascularized liver scaffolds that can maintain blood perfusion at physiological pressures might eventually help to overcome the chronic shortage of transplantable human livers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.